CTOs on the Move

Simplex Sciences

www.simplexsciences.com

 
High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ABS Lifesciences

ABS Lifesciences is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artisan Pharma

Artisan Pharma is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.

Arcellx

Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.

Good Therapeutics

Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.